Human Hematopoietic Stem/Progenitor Cells in Type One Diabetes Mellitus Treatment : Is There an Ideal Candidate?
Type 1 diabetes mellitus (T1DM) is a highly prevalent autoimmune disease causing the destruction of pancreatic islet β-cells. The resulting insulin production deficiency leads to a lifelong need for insulin re-placement therapy, systemic complications, and reduced life quality and expectancy. Cell therapy has been extensively attempted to restore insulin independence (IID), and autologous nonmyeloablative hematopoietic stem cell transplantation (AHST) has appeared to give the most promising results, but with a highly variable quote of patients achieving IID across the studies. We performed a comprehensive review of the trials involving stem cells, and in particular AHST, for the treatment of T1DM. We then pooled the patients enrolled in the different trials and looked for the patient characteristics that could be associated with the achievement of IID. We found a significantly higher probability of achieving IID in older patients (OR 1.17, 95%CI 1.06-1.33, p = 0.002) and a significantly lower probability in patients with a history of ketoacidosis (OR 0.23, 95%CI 0.06-0.78, p = 0.023). This suggests that there could be a population of patients more likely to benefit from AHST, but further data would be required to depict the profile of the ideal candidate.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Cells - 12(2023), 7 vom: 30. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Carulli, Ermes [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
AHST |
|---|
| Anmerkungen: |
Date Completed 14.04.2023 Date Revised 27.04.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3390/cells12071054 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355524864 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355524864 | ||
| 003 | DE-627 | ||
| 005 | 20231226064531.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/cells12071054 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1185.xml |
| 035 | |a (DE-627)NLM355524864 | ||
| 035 | |a (NLM)37048127 | ||
| 035 | |a (PII)1054 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Carulli, Ermes |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Human Hematopoietic Stem/Progenitor Cells in Type One Diabetes Mellitus Treatment |b Is There an Ideal Candidate? |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.04.2023 | ||
| 500 | |a Date Revised 27.04.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Type 1 diabetes mellitus (T1DM) is a highly prevalent autoimmune disease causing the destruction of pancreatic islet β-cells. The resulting insulin production deficiency leads to a lifelong need for insulin re-placement therapy, systemic complications, and reduced life quality and expectancy. Cell therapy has been extensively attempted to restore insulin independence (IID), and autologous nonmyeloablative hematopoietic stem cell transplantation (AHST) has appeared to give the most promising results, but with a highly variable quote of patients achieving IID across the studies. We performed a comprehensive review of the trials involving stem cells, and in particular AHST, for the treatment of T1DM. We then pooled the patients enrolled in the different trials and looked for the patient characteristics that could be associated with the achievement of IID. We found a significantly higher probability of achieving IID in older patients (OR 1.17, 95%CI 1.06-1.33, p = 0.002) and a significantly lower probability in patients with a history of ketoacidosis (OR 0.23, 95%CI 0.06-0.78, p = 0.023). This suggests that there could be a population of patients more likely to benefit from AHST, but further data would be required to depict the profile of the ideal candidate | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a AHST | |
| 650 | 4 | |a CD34 | |
| 650 | 4 | |a HSPCs | |
| 650 | 4 | |a T1DM | |
| 650 | 4 | |a cardiovascular disease | |
| 650 | 4 | |a cell therapy | |
| 650 | 4 | |a diabetes | |
| 650 | 7 | |a Insulin |2 NLM | |
| 650 | 7 | |a Insulin, Regular, Human |2 NLM | |
| 700 | 1 | |a Pompilio, Giulio |e verfasserin |4 aut | |
| 700 | 1 | |a Vinci, Maria Cristina |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cells |d 2011 |g 12(2023), 7 vom: 30. März |w (DE-627)NLM227066421 |x 2073-4409 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2023 |g number:7 |g day:30 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/cells12071054 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2023 |e 7 |b 30 |c 03 | ||